Status:

WITHDRAWN

Mechanisms of Metabolic Regulation of Resveratrol on Humans With Metabolic Syndrome

Lead Sponsor:

University of California, San Francisco

Conditions:

Insulin Resistance

Eligibility:

All Genders

50+ years

Phase:

PHASE2

Brief Summary

Sirtuin activators may prove useful in treating age-related diseases and extending lifespan in humans. Resveratrol (RSV), a polyphenol found in red wine, has been shown in vitro to enhance SIRT1 activ...

Detailed Description

Hypotheses for this study: 4 weeks of supplementation with RSV 5.0 grams daily compared to placebo control in individuals with insulin resistance will: 1) Increase insulin sensitivity (assessed by th...

Eligibility Criteria

Inclusion

  • Adults ages 50 years or older
  • Women ages 50 years and older who are postmenopausal, defined as no menses for the previous 12 months
  • BMI 25 to 35
  • Waist-to-hip circumference ratios for men \>0.95, for women \>0.85
  • HOMA-IR score from fasting plasma glucose and serum insulin levels \>2.7
  • A diet consisting of \> 40% calories from fat; and
  • Sedentary, defined as no formal exercise program and less than 30 minutes physical activity weekly.

Exclusion

  • Active malignancy or tumor or other condition that would severely limit life expectancy
  • Any type of major surgery during the last 3 months
  • Psychiatric disorders with currently active manifestations
  • Insulin-dependent diabetes
  • Any chronic medications except for hormone replacement therapy. Vitamin supplements (of any type) are not allowed during the study, but are acceptable if the participant agrees to a 2 week washout period before participation in the study
  • Active symptoms suggestive of an acute coronary syndrome or decompensated heart failure
  • Currently on low fat diet or special diet (i.e. weight loss)
  • Excessive alcohol intake (\>3 glasses of wine/1 six pack of beer daily)
  • Concurrent participation in any drug studies or studies that require sample of a body fluid (or having finished in the past 6 months)
  • Non-English speakers
  • Abnormal LFTs.

Key Trial Info

Start Date :

May 1 2007

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

August 1 2008

Estimated Enrollment :

Patients enrolled

Trial Details

Trial ID

NCT00654667

Start Date

May 1 2007

End Date

August 1 2008

Last Update

March 4 2015

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

University of California

San Francisco, California, United States, 94143-0608